NewcelX Ltd. (NCEL)
NASDAQ: NCEL · Real-Time Price · USD
3.755
-0.045 (-1.18%)
Jul 24, 2026, 4:00 PM EDT - Market closed
NewcelX Employees
As of December 31, 2025, NewcelX had 12 total employees, including 9 full-time and 3 part-time employees. The number of employees decreased by 3 or -20.00% compared to the previous year.
Employees
12
Change (1Y)
-3
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$691,667
Market Cap
20.22M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 12 | -3 | -20.00% | 9 | 3 |
| Dec 31, 2024 | 15 | 3 | 25.00% | 11 | 4 |
| Dec 31, 2023 | 12 | -19 | -61.29% | 12 | 0 |
| Dec 31, 2022 | 31 | -1 | -3.13% | 31 | 0 |
| Dec 31, 2020 | 32 | - | - | 28 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Daré Bioscience | 24 |
| Jasper Therapeutics | 22 |
| NeuroSense Therapeutics | 17 |
| Atossa Therapeutics | 16 |
| Werewolf Therapeutics | 14 |
| Cellectar Biosciences | 11 |
| Neuphoria Therapeutics | 8 |
NCEL News
- 10 days ago - NewcelX announces Brazil patent for cell selection, enrichment technology - TheFly
- 12 days ago - NewcelX initiated with a Buy at Laidlaw - TheFly
- 17 days ago - NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - GlobeNewsWire
- 24 days ago - NewcelX completes Type B Pre-IND meeting with FDA for NCEL-101 - TheFly
- 24 days ago - NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes - GlobeNewsWire
- 5 weeks ago - NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform - GlobeNewsWire
- 2 months ago - NewcelX submits NCEL-101 pre-investigational new drug briefing package to FDA - TheFly
- 2 months ago - NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes - GlobeNewsWire